SOURCE: Addison-Davis Diagnostics, Inc.

July 20, 2005 08:31 ET

Addison-Davis Diagnostics Signs Strategic Sales and Marketing Agreement With Ohio Surgical, LLC

WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- July 20, 2005 -- Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) is pleased to announce that they have signed a strategic sales and marketing agreement with Ohio Surgical, LLC. Ohio Surgical will be responsible for setting up and maintaining sales and distribution channels for "Drug Stop," the Addison-Davis on site drug screening test, which has already received FDA 510K and Over-The-Counter Clearance.

Ohio Surgical, LLC ( is an Ohio-based company serving the healthcare community for 25 years. They specialize in innovative, niche products and services that represent quality and value not found elsewhere in the healthcare market. Ohio Surgical provides diversified products from diagnostic to specialty infusion products.

"We are excited about working with Addison-Davis. Their products are a dynamic and innovative addition to the products we have been providing our customers for years," stated Timothy Hallagan, President of Ohio Surgical, LLC.

"Addison-Davis believes that the strength of Ohio Surgical's 25 year experience will have a dramatic effect on the Company's sales efforts," stated Edward W. Withrow III, CEO of Addison Davis Diagnostics, Inc.

About Addison-Davis

Addison-Davis Diagnostics, Inc. is responding to industry demands by supplying quick response diagnostic tests that are user friendly, produce fast simple results and are less costly, less problematic and less time consuming. Addison-Davis is currently focused on bringing fast and reliable "Point-of-care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, certain branches of the Government and the Workplace environment for drugs-of-abuse and medical conditions and diseases.

For more information please visit our website or contact Matt Maguire 1-866 THE APPL(E).

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • For more information:
    please visit our website:

    Matt Maguire
    1-866 THE APPL(E)